Approaches, Progress, and Challenges to Hepatitis C Vaccine Development

Overview

Journal Gastroenterology

Specialty Gastroenterology

Date 2018 Oct 1

PMID 30268785

Citations 117

Authors

Justin R Bailey

Eleanor Barnes

Andrea L Cox

Affiliations

Soon will be listed here.

Abstract

Risk factors for hepatitis C virus (HCV) infection vary, and there were an estimated 1.75 million new cases worldwide in 2015. The World Health Organization aims for a 90% reduction in new HCV infections by 2030. An HCV vaccine would prevent transmission, regardless of risk factors, and significantly reduce the global burden of HCV-associated disease. Barriers to development include virus diversity, limited models for testing vaccines, and our incomplete understanding of protective immune responses. Although highly effective vaccines could prevent infection altogether, immune responses that increase the rate of HCV clearance and prevent chronic infection may be sufficient to reduce disease burden. Adjuvant envelope or core protein and virus-vectored nonstructural antigen vaccines have been tested in healthy volunteers who are not at risk for HCV infection; viral vectors encoding nonstructural proteins are the only vaccine strategy to be tested in at-risk individuals. Despite development challenges, a prophylactic vaccine is necessary for global control of HCV.

Citing Articles

Vaccine Development T-cell (MHC-I) Epitopes Identification Against the Indian HCV Genotype: An Approach Based on Immunoinformatic.

Iyyanar S, Ravi S Mol Biotechnol. 2025; .

PMID: 39994132 DOI: 10.1007/s12033-025-01398-5.

TCellPredX: A Novel Approach for Accurate Prediction of Hepatitis C Virus Linear T Cell Epitopes.

Ge F, Li H, Zhang M, Arif M, Alam T ACS Omega. 2025; 9(52):51494-51507.

PMID: 39758636 PMC: 11696426. DOI: 10.1021/acsomega.4c08715.

Beyond the Liver: A Comprehensive Review of Strategies to Prevent Hepatocellular Carcinoma.

Polpichai N, Saowapa S, Danpanichkul P, Chan S, Sierra L, Blagoie J J Clin Med. 2024; 13(22).

PMID: 39597914 PMC: 11594971. DOI: 10.3390/jcm13226770.

Minicircle-based vaccine induces potent T-cell and antibody responses against hepatitis C virus.

Czarnota A, Raszplewicz A, Slawinska A, Bienkowska-Szewczyk K, Grzyb K Sci Rep. 2024; 14(1):26698.

PMID: 39496832 PMC: 11535267. DOI: 10.1038/s41598-024-78049-3.

Like a Rolling Stone? A Review on Spontaneous Clearance of Hepatitis C Virus Infection.

Rzymski P, Brzdek M, Dobrowolska K, Poniedzialek B, Murawska-Ochab A, Zarebska-Michaluk D Viruses. 2024; 16(9).

PMID: 39339862 PMC: 11435954. DOI: 10.3390/v16091386.

References

Ray S, Wang Y, Laeyendecker O, Ticehurst J, Villano S, Thomas D . Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol. 1999; 73(4):2938-46. PMC: 104053. DOI: 10.1128/JVI.73.4.2938-2946.1999. View

Flint M, Thomas J, Maidens C, Shotton C, Levy S, Barclay W . Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J Virol. 1999; 73(8):6782-90. PMC: 112763. DOI: 10.1128/JVI.73.8.6782-6790.1999. View

Forns X, Purcell R, Bukh J . Quasispecies in viral persistence and pathogenesis of hepatitis C virus. Trends Microbiol. 1999; 7(10):402-10. DOI: 10.1016/s0966-842x(99)01590-5. View

Forns X, Payette P, Ma X, Satterfield W, Eder G, MUSHAHWAR I . Vaccination of chimpanzees with plasmid DNA encoding the hepatitis C virus (HCV) envelope E2 protein modified the infection after challenge with homologous monoclonal HCV. Hepatology. 2000; 32(3):618-25. DOI: 10.1053/jhep.2000.9877. View

Hadlock K, Lanford R, Perkins S, Rowe J, Yang Q, Levy S . Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol. 2000; 74(22):10407-16. PMC: 110915. DOI: 10.1128/jvi.74.22.10407-10416.2000. View

Chang K, Thimme R, Melpolder J, Oldach D, Pemberton J, McHutchison J . Differential CD4(+) and CD8(+) T-cell responsiveness in hepatitis C virus infection. Hepatology. 2000; 33(1):267-76. DOI: 10.1053/jhep.2001.21162. View

Polakos N, Drane D, Cox J, Ng P, Selby M, Chien D . Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol. 2001; 166(5):3589-98. DOI: 10.4049/jimmunol.166.5.3589. View

Bassett S, Guerra B, Brasky K, Miskovsky E, Houghton M, Klimpel G . Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection. Hepatology. 2001; 33(6):1479-87. DOI: 10.1053/jhep.2001.24371. View

Lanford R, Bigger C, Bassett S, Klimpel G . The chimpanzee model of hepatitis C virus infections. ILAR J. 2001; 42(2):117-26. DOI: 10.1093/ilar.42.2.117. View

10.

Ward S, Lauer G, Isba R, Walker B, Klenerman P . Cellular immune responses against hepatitis C virus: the evidence base 2002. Clin Exp Immunol. 2002; 128(2):195-203. PMC: 1906407. DOI: 10.1046/j.1365-2249.2002.01840.x. View

11.

Mehta S, Cox A, Hoover D, Wang X, Mao Q, Ray S . Protection against persistence of hepatitis C. Lancet. 2002; 359(9316):1478-83. DOI: 10.1016/S0140-6736(02)08435-0. View

12.

Major M, Mihalik K, Puig M, Rehermann B, Nascimbeni M, Rice C . Previously infected and recovered chimpanzees exhibit rapid responses that control hepatitis C virus replication upon rechallenge. J Virol. 2002; 76(13):6586-95. PMC: 136282. DOI: 10.1128/jvi.76.13.6586-6595.2002. View

13.

Bartosch B, Dubuisson J, Cosset F . Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J Exp Med. 2003; 197(5):633-42. PMC: 2193821. DOI: 10.1084/jem.20021756. View

14.

Nascimbeni M, Mizukoshi E, Bosmann M, Major M, Mihalik K, Rice C . Kinetics of CD4+ and CD8+ memory T-cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol. 2003; 77(8):4781-93. PMC: 152131. DOI: 10.1128/jvi.77.8.4781-4793.2003. View

15.

Farci P, Alter H, Govindarajan S, Wong D, Engle R, Lesniewski R . Lack of protective immunity against reinfection with hepatitis C virus. Science. 1992; 258(5079):135-40. DOI: 10.1126/science.1279801. View

16.

Shoukry N, Grakoui A, Houghton M, Chien D, Ghrayeb J, Reimann K . Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med. 2003; 197(12):1645-55. PMC: 2193956. DOI: 10.1084/jem.20030239. View

17.

Martell M, Esteban J, Quer J, Genesca J, Weiner A, Esteban R . Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol. 1992; 66(5):3225-9. PMC: 241092. DOI: 10.1128/JVI.66.5.3225-3229.1992. View

18.

Grakoui A, Shoukry N, Woollard D, Han J, Hanson H, Ghrayeb J . HCV persistence and immune evasion in the absence of memory T cell help. Science. 2003; 302(5645):659-62. DOI: 10.1126/science.1088774. View

19.

Bartosch B, Bukh J, Meunier J, Granier C, Engle R, Blackwelder W . In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A. 2003; 100(24):14199-204. PMC: 283569. DOI: 10.1073/pnas.2335981100. View

20.

Rollier C, Depla E, Drexhage J, Verschoor E, Verstrepen B, Fatmi A . Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol. 2003; 78(1):187-96. PMC: 303385. DOI: 10.1128/jvi.78.1.187-196.2004. View